ValuEngine upgraded shares of ENDRA Life Sciences (NASDAQ:NDRA) from a hold rating to a buy rating in a research report report published on Thursday morning, ValuEngine reports.
Other research analysts have also issued reports about the company. Lake Street Capital assumed coverage on ENDRA Life Sciences in a research report on Monday, May 20th. They issued a buy rating on the stock. Dougherty & Co began coverage on ENDRA Life Sciences in a research report on Thursday, June 13th. They issued a buy rating on the stock. Finally, HC Wainwright began coverage on ENDRA Life Sciences in a report on Monday, July 15th. They set a buy rating and a $6.00 price objective on the stock.
NDRA stock traded down $0.09 during mid-day trading on Thursday, hitting $1.35. The stock had a trading volume of 1,100 shares, compared to its average volume of 70,102. ENDRA Life Sciences has a 1-year low of $0.90 and a 1-year high of $5.75. The business’s fifty day moving average price is $1.59. The stock has a market cap of $9.15 million, a PE ratio of -0.64 and a beta of 1.43.
ENDRA Life Sciences (NASDAQ:NDRA) last issued its earnings results on Tuesday, May 14th. The company reported ($0.37) earnings per share for the quarter. As a group, equities research analysts predict that ENDRA Life Sciences will post -1.03 EPS for the current year.
In related news, insider Michael Milos Thornton acquired 30,000 shares of the stock in a transaction dated Thursday, May 16th. The shares were acquired at an average price of $1.13 per share, with a total value of $33,900.00. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 11.40% of the company’s stock.
Several hedge funds and other institutional investors have recently modified their holdings of the company. Virtu Financial LLC increased its holdings in shares of ENDRA Life Sciences by 109.2% during the 1st quarter. Virtu Financial LLC now owns 28,602 shares of the company’s stock valued at $47,000 after acquiring an additional 14,930 shares during the last quarter. ICM Asset Management Inc. WA boosted its stake in ENDRA Life Sciences by 3.2% during the 2nd quarter. ICM Asset Management Inc. WA now owns 696,201 shares of the company’s stock valued at $1,191,000 after purchasing an additional 21,875 shares during the period. Finally, Geode Capital Management LLC bought a new stake in ENDRA Life Sciences during the 4th quarter valued at approximately $71,000. 17.21% of the stock is currently owned by institutional investors and hedge funds.
ENDRA Life Sciences Company Profile
ENDRA Life Sciences Inc develops medical imaging technology based on the thermos-acoustic effect that improves the sensitivity and specificity of clinical ultrasound. It offers diagnostic imaging technologies, such as computed tomography, magnetic resonance imaging, and ultrasound that allow physicians to look inside a person's body to guide treatment or gather information about medical conditions, such as broken bones, cancers, signs of heart disease, or internal bleeding.
Recommended Story: What is a management fee?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for ENDRA Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ENDRA Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.